CD274 and neoplasm: In the IMmotion 151 trial, the magnitude of benefit derived from the combination therapy with atezolizumab plus bevacizumab increased in patients with PD-L1 expression by more than 1% of tumor-infiltrating lymphocytes compared with the ITT population (45).